Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sample.
- Who it may be relevant to
- Registry conditions: Systemic Lupus Erythematosus, Physiopathology. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus
Overview
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.
Detailed description
The role of FcRn in autoimmune diseases remains to be clarified, but it has been implicated in numerous pathophysiological mechanisms, notably in the management of immune complexes or the recycling of autoantibodies. In humans, this role in the metabolism of autoantibodies has recently led to the development of therapeutic antibodies for autoimmune diseases such as autoimmune thrombocytopenia and myasthenia.
The lupus erythematosus is an auto-immune disease mediated by IgG and immune complexes characterized by a high diversity of autoantibodies and a large dysregulation of the immune system in all it's components, one of them being iNKT cells.
Studies in patients or in lupus mouse models have shown a decrease in iNKT cells correlated with disease activity as well as tissue infiltration in relation to clinical manifestations. Their actual role in this pathology remains to be clarified between regulatory or pro-inflammatory effect.
The possible role of iNKT as a regulatory cell in lupus pathology and the possible involvement of FcRn in their development reinforces the interest of their simultaneous study in humans.
The aim of this study will be to evaluate the impact of the expression of FcRn and other Fc gamma receptors cooperating with FcRn (Fc gamma RII and RIII) in iNKT cells in lupus patients in relation to disease activity and therapy. This study will be conducted in parallel on monocytes, cells involved in the metabolism of immune complexes and likely to be activated by iNKT cells. These results will be compared to healthy controls and integrated into mechanistic studies in a mouse model.
Interventions
- Biological Blood sample
Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
Primary outcome measures
- FcRn Expression analysis in Circulating iNKT lymphocytes [Time frame: through study completion, an average of 3 year]
- FcRn Expression analysis in circulating monocytes [Time frame: through study completion, an average of 3 year]
- FcgammaRII Expression analysis in Circulating iNKT lymphocytes [Time frame: through study completion, an average of 3 year]
- FcgammaRII Expression analysis in circulating monocytes [Time frame: through study completion, an average of 3 year]
- FcgammaRIII Expression analysis in Circulating iNKT lymphocytes [Time frame: through study completion, an average of 3 year]
- FcgammaRIII Expression analysis in in circulating monocytes [Time frame: through study completion, an average of 3 year]
Secondary outcome measures (6)
- corticotherapy [Time frame: through study completion, an average of 3 year]
- hydroxychloroquine [Time frame: through study completion, an average of 3 year]
- immunosuppressants outside of biotherapy: methotrexate, azathioprine, mycophenolate mofetil [Time frame: through study completion, an average of 3 year]
- biotherapy: belimumab and rituximab [Time frame: through study completion, an average of 3 year]
- lupus disease activity [Time frame: through study completion, an average of 3 year]
- albumin and IgG levels [Time frame: through study completion, an average of 3 year]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
- Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
- Lupus patient, newly diagnosed or known, untreated or in relapse
- Lupus patient considered stable by the treating practitioner
- Requiring blood sampling for follow-up
Exclusion criteria
- Main autoimmune disease other than lupus
- Patient under legal protection, guardianship or curators
- Opposition to data processing
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
France · 1 center
- University Hospital — Tours
Identifiers
NCT: NCT05859191 · DR230103-FiNK LUPUS